by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract BACKGROUND Despite significant astrocytic involvement in Parkinson’s disease (PD), the knowledge regarding the role of reactive astrogliosis is still at the surface level; largely due to lack of specific biomarkers to track these processes. Novel...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION One of the pathological hallmarks of Alzheimer’s disease (AD) is the accumulation of amyloid beta 42 (Aβ42). Decreased venous drainage may enhance Aβ42 accumulation. We aimed to compare venous cross-sectional area (CSA) of AD patients to...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION There is an unmet need for tools to quantify dementia risk during its multi-decade preclinical/prodromal phase, given that current biomarkers predict risk over shorter follow-up periods and are specific to Alzheimer’s disease. METHODS Using...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION The presence of psychosis in Alzheimer’s disease (AD) is suggested to be associated with distinct molecular and neuropathological profiles in the brain. METHODS We assessed brain DNA methylation in AD donors with psychosis (AD+P) and...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) diagnosis centers on cognitive impairment despite other early indicators like neuropsychiatric symptoms (NPSs) and amyloid beta (Aβ) accumulation. This study examined how cognition, NPS, and Aβ changes are...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract The characteristic events in neurodegenerative diseases (NDDs) encompass protein misfolding, aggregation, accumulation, and their related cellular dysfunction, synaptic function loss. While distinct proteins are implicated in the pathological processes of...
